Is SABS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SABS. It does not provide personalized investment advice.

SABS (SAB Biotherapeutics, Inc. Common Stock) Stock Analysis - Financials

SAB Biotherapeutics, Inc. Common Stock (SABS) is a publicly traded Healthcare sector company. As of July 26, 2026, SABS trades at $3.51 with a market cap of $268.39M and a P/E ratio of 15.96. SABS moved -1.96% today. Year to date, SABS is -6.15%; over the trailing twelve months it is +35.00%. Its 52-week range spans $1.00 to $6.60. Analyst consensus is strong buy with an average price target of $12.00. Rallies surfaces SABS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are SABS's key financials?

SABS financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. SABS recently traded at $3.51. Market cap is $268.39M. P/E ratio is 15.96. Revenue is $0.

SABS Key Metrics

Key financial metrics for SABS
Metric	Value
Price	$3.51
Market Cap	$268.39M
P/E Ratio	15.96
EPS	$0.22
Dividend Yield	0.00%
52-Week High	$6.60
52-Week Low	$1.00
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$13.27M
Gross Margin	0.00%

SABS Analyst Consensus

8 analysts cover SABS: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.00.

Common questions about SABS

What are SABS's key financials?: SABS financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. SABS recently traded at $3.51. Market cap is $268.39M. P/E ratio is 15.96. Revenue is $0.
Is SABS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SABS. It does not provide personalized investment advice.